Pfizer to pay $35M to settle drug marketing case

Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses.

The states' attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained to encourage doctors to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.

Rapamune was approved in 1999 for use in . Promoting drugs for uses not cleared by the Food and Drug Administration is illegal.

Pfizer agreed to pay nearly $491 million in July 2013 to resolve a similar investigation by the Department of Justice.

Pfizer said in a statement that the alleged activity occurred before it acquired Wyeth. The company did not admit any wrongdoing or liability as part of the settlement.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pfizer to pay $491M to resolve drug marketing case (Update)

Jul 30, 2013

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

Endo Health to pay $192.7M in gov't settlement

Feb 22, 2014

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.

Pfizer will buy NextWave Pharma for up to $700M

Oct 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Recommended for you

Discovery helps to spot what makes a good drug

2 hours ago

(Medical Xpress)—A new test developed by researchers from the University of Manchester could revolutionise the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early ...

Merck completes sale of consumer unit to Bayer

19 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments